Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study

Background. Obesity is increasingly prevalent among people with human immunodeficiency virus (HIV, PWH). Obesity can reduce drug exposure; however, limited data are available for long-acting (LA) antiretrovirals. We performed in silico trials using physiologically based pharmacokinetic (PBPK) modeling to determine the effect of obesity on the exposure of LA cabotegravir and rilpivirine after the initial injection and after multiple injections. Methods. Our PBPK model was verified against available clinical data for LA cabotegravir and rilpivirine in normal weight/ overweight (body mass index [BMI] <30 kg/m(2)) and in obese (BMI >30 kg/m(2)). Cohorts of virtual individuals were generated to simulate the exposure of LA cabotegravir/rilpivirine up to a BMI of 60 kg/m(2). The fold change in LA cabotegravir and rilpivirine exposures (area under the curve [AUC]) and trough concentrations (C-min) for monthly and bimonthly administration were calculated for various BMI categories relative to normal weight (18.5-25 kg/m(2)). Results. Obesity was predicted to impact more cabotegravir than rilpivirine with a decrease in cabotegravir AUC and C-min of >35% for BMI >35 kg/m(2) and in rilpivirine AUC and C-min of >18% for BMI >40 kg/m(2) at steady-state. A significant proportion of morbidly obese individuals were predicted to have both cabotegravir and rilpivirine C-min below the target concentration at steady-state with the bimonthly administration, but this was less frequent with the monthly administration. Conclusions. Morbidly obese PWH are at risk of presenting suboptimal C-min for cabotegravir/rilpivirine after the first injection but also at steady-state particularly with the bimonthly administration. Therapeutic drug monitoring is advised to guide dosing interval adjustment.